Puma Biotechnology, Inc. PBYI · NASDAQ
$9.83 -6.56% (-$0.69)
Summary
77 / 100 · Bulios Score
What speaks for it
- Earnings per share grew by 211% a year over the last 3 years.
- It earns 18 USD a year on every 100 USD of invested capital.
- It holds more cash than debt: $36.5M against $4.82M.
- Out of every 100 USD of revenue, 12 USD is left as net profit.
What to watch
- The share price is above the Bulios Fair Price.
- Revenue grew by only 0.0% a year over the last 3 years.
Bulios Scoring describes a company's quality and track record, not its future return. A high score is not a buy signal. Learn more
Score in detailPrice
Is it expensive?
Looks expensiveBulios Fair Price is an estimate of a stock's fair value from the Bulios valuation model. It is an input for your own analysis, not investment advice. How does it work?
Today you pay 20.3 USD for 1 USD of yearly profit. Over the last five years it was 23,762.8 USD on average.
Valuation in detailIs it growing?
SlowlyRevenue (USD)
Diluted EPS (USD)
- Analyst estimate
Revenue grew by 0.3% a year over 5 years. Over the last 3 years it grew by 0.0% a year. Earnings per share grew by 211% a year over the last 3 years.
Growth in detailDoes it make money?
Very wellWhere 100 USD of revenue goes
- Cost of sales 25 USD
- Research and development 31 USD
- Sales and administration 31 USD
- Taxes and other 1.6 USD
- Net profit 12 USD
Net profit, industry median (Biotechnology) -7.1 USD
Out of every 100 USD of revenue, 12 USD is left as net profit.
Profitability in detailIs it financially healthy?
YesIt could repay all its debt from a single year of free cash flow. It holds more cash than debt.
Financial health in detailDoes it pay a dividend?
NoIt pays no dividend.
Dividends in detailWhat do analysts expect?
Mildly positive- Buy 8
- Hold 8
- Sell 4
No analyst has published a price target.
40% of the analysts recommend buying.
Analysts in detailWhat does it earn on?
Fiscal year 2025By product
- Product 89%
- Royalty 11%
By region
The company reports no revenue by region.
Product brings in 89% of revenue. Royalty grew fastest, by 18% a year.
Segments in detail